Teyi Pharmaceutical Group Co Ltd Asset Resilience Ratio
Teyi Pharmaceutical Group Co Ltd asset resilience ratio. Teyi Pharmaceutical Group Co Ltd (002728) has an Asset Resilience Ratio of 9.66% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Teyi Pharmaceutical Group Co Ltd (002728) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Teyi Pharmaceutical Group Co Ltd (2017–2025)
Asset resilience ratio of Teyi Pharmaceutical Group Co Ltd from 2017 to 2025. This chart shows how Teyi Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Read Teyi Pharmaceutical Group Co Ltd (002728) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Teyi Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Teyi Pharmaceutical Group Co Ltd (002728) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥225.00 Million | 9.66% |
| Total Liquid Assets | CN¥225.00 Million | 9.66% |
Asset Resilience Insights
- Limited Liquidity: Teyi Pharmaceutical Group Co Ltd maintains only 9.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Teyi Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Teyi Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Teyi Pharmaceutical Group Co Ltd Asset Resilience Ratio by Year (2017–2025)
Teyi Pharmaceutical Group Co Ltd asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Teyi Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.09% | CN¥210.00 Million ≈ $30.73 Million |
CN¥2.31 Billion ≈ $338.23 Million |
+9.48pp |
| 2022-12-31 | -0.40% | CN¥-10.11 Million ≈ $-1.48 Million |
CN¥2.55 Billion ≈ $372.50 Million |
-11.48pp |
| 2020-12-31 | 11.08% | CN¥250.00 Million ≈ $36.58 Million |
CN¥2.26 Billion ≈ $330.14 Million |
-8.86pp |
| 2019-12-31 | 19.94% | CN¥450.00 Million ≈ $65.85 Million |
CN¥2.26 Billion ≈ $330.24 Million |
+6.98pp |
| 2017-12-31 | 12.96% | CN¥250.00 Million ≈ $36.58 Million |
CN¥1.93 Billion ≈ $282.27 Million |
-- |
About Teyi Pharmaceutical Group Co Ltd
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patented medicines, pharmaceutical preparations, raw materials, and products in the People's Republic of China. The company's products are used in respiratory system, cardiovascular and cerebrovascular, respiratory, cardiovascular, and digestive systems. The company was formerly known as Gua… Read more